CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Mitochondria: from powerhouses of cells to hubs in antitumor immunity.
Mitochondria: from powerhouses of cells to hubs in antitumor immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫检查点抑制剂和CAR-T 细胞疗法构成当前免疫治疗的基石,但其疗效常受到免疫抑制性肿瘤微环境的限制。近期,线粒体被认为是重要的代谢-免疫枢纽,对肿瘤进展、转移及免疫逃逸具有关键支持作用。然而,这一认识尚未转化为对相关机制或治疗潜力的清晰理解。本综述总结线粒体在细胞代谢调节中的作用,重点关注肿瘤微环境内癌细胞及免疫细胞中的线粒体介导代谢重编程。随后,我们讨论通过靶向癌细胞和CAR-T 细胞代谢重编程增强抗肿瘤免疫的治疗机会。最后,我们展望新兴线粒体靶向策略,包括线粒体疫苗、精准线粒体DNA编辑及工程化线粒体移植。
While immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies constitute the cornerstone of current immunotherapy, their efficacy is often limited by, most notably, the immunosuppressive tumor microenvironment. Recently, mitochondria are recognized as pivotal metabolic-immune hubs that critically support tumor progression, metastasis, and immune evasion.
However, this insight has not yet translated into a clear understanding of the underlying mechanisms or their therapeutic potential. This review summarizes the role of mitochondria in cellular metabolic regulation, with a focus on mitochondrial-mediated metabolic reprogramming in cancer and immune cells within the tumor microenvironment.
We then discuss therapeutic opportunities to potentiate antitumor immunity by targeting mitochondrial reprogramming in cancer and CAR-T cells.
Finally, we offer a forward-looking perspective on emerging mitochondria-targeted strategies, such as mitochondrial vaccines, precise mtDNA editing, and engineered mitochondrial transplantation.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。